All In Biotech

Drug Trial Radar · NCT06182696

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory Multiplemyeloma

Last checked: Nov 19, 2026Latest source record: May 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

83

Planned (sponsor's estimate)

Start

Oct 26, 2023

Primary completion

Nov 30, 2026

Study completion Aug 31, 2028

Sponsor

Lead sponsor
OriCell Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM

Conditions

  • Relapsed and/or Refractory Multiple Myeloma

Interventions

  • OriCAR-017Biological

    GPCRC5D-directed chimeric antigen receptor modified T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose of OriCAR-017-P1Time frame: Up to 28 days
  2. Dose-limiting toxicity (DLT)Time frame: Up to 28 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Hospital

    Beijing, China · Not yet recruiting

  • The First Affiliated Hospital with Nanjing Medical University

    Nanjing, China · Not yet recruiting

  • Tongji Hospital of Tongji University

    Shanghai, China · Not yet recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • The First Affiliated Hospital College of Medicine Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.